Loading
Life sciences · Journal article
Frontiers in Immunology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background T-cell function is regulated by immunometabolism, and lysosomes are signaling hubs. CD68 (LAMP4), traditionally regarded as a monocyte/macrophage marker, has been largely neglected in T cell biology. We aimed to assess the link between CD68 expression in T cells and anti-PD-1 response in lung cancer, and its potential as an early dynamic biomarker in peripheral blood CD8 + T cells. Methods We analyzed transcriptomic (GSE126044, GSE135222, GSE166449) and single-cell (GSE207422) data from anti-PD-1-treated lung cancer cohorts to identify lysosome related pathways and key genes, validated with peripheral blood CD8 + T cell data (GSE111414). Prospectively, we enrolled lung cancer patients receiving anti-PD-1 therapy, collecting peripheral blood at baseline and week 3. Flow cytometry measured CD68 in CD8 + T cells and subsets, assessing association with response, progression-free survival (PFS), and functional markers (granzyme B, perforin, Ki-67, CD69, IFN-γ, IL-1β). Results Responders showed enrichment of lysosome pathways and upregulation of 8 lysosome related genes including CD68, positively correlated with monocyte and T cell infiltration. Single-cell data linked CD68 expression in T cell to favorable response. After one cycle, the proportion of CD8 + CD68 + T cells was lower in non-responders ( P<0.05 ), with AUC 0.803 ( P=0.044 ) and cutoff 1.015%, stratifying PFS ( P=0.0225 ). CD68 was highest in naïve T cells at baseline, but decreased across subsets after treatment in non-responders (all P<0.01 ). Functionally, compared with CD8 + CD68 - T cells, CD8 + CD68 + T cells exhibited lower expression of granzyme B and perforin but higher expression of Ki-67, CD69, IFN-γ, and IL-1β (all P<0.001 ), suggesting a CD8 + T cell state characterized by lower cytotoxicity and enhanced proliferative and cytokine producing capacities, accompanied by a tissue residency associated phenotype. Conclusion CD8 + CD68 + T cells exhibit lower cytotoxicity but greater proliferative and cytokine producing capacities, together with a tissue residency associated phenotype, suggesting a precursor-like state. Low CD68 expression in tumor-infiltrating T cells and the post-treatment reduction of CD68 expression in peripheral blood CD8 + T cells are associated with resistance to anti-PD-1 therapy in lung cancer. These findings suggest that CD8 + CD68 + T cells may serve as a potential early dynamic immune biomarker for monitoring and assessing response to anti-PD-1 therapy in lung cancer.